RANI News and Press, Rani Therapeutics Holdings Inc. From 03/29/22

Rani Therapeutics Holdings, Inc. (RANI) Q4 2021 Earnings Conference Call March 29, 2022, 04:30 PM ET Company Participants Laurence Watts - Managing Director, Gilmartin Group LLC Talat Imran - CEO Svai Sanford - Chief Financial Officer Mir Hashim - Chief Scientific Officer Conference Call Part...

Rani Therapeutics press release (NASDAQ:RANI): Q4 GAAP EPS of -$0.27 misses by $0.04. Cash and cash equivalents $117.45M For further details see: Rani Therapeutics GAAP EPS of -$0.27 misses by $0.04

- Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - - Unveiled the high-capacity RaniPill ™ HC , capable of delivering payloads of up to 20 mg - - Strengthened Board with the appointments of Lyn Baranowski and Lisa ...

SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company will release...

Rani Therapeutics (NASDAQ:RANI) began a phase 1 study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34), to treat osteoporosis, delivered via RaniPill capsule. Osteoporosis is a disorder that causes bones to become weak and brittle. PTH is one of the treatm...

SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the initiation of a Phase 1 s...

- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up to 20mg payload has the potential to unlock more than 50 additional biologics for internal development or partnership - ...

SAN JOSE, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the appointment of Lisa Romett...

Rani Therapeutics (NASDAQ:RANI): Q3 GAAP EPS of -$0.16 beats by $0.02. Cash and cash equivalents of $129.74M Press Release For further details see: Rani Therapeutics EPS beats by $0.02

SAN JOSE, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quart...